Other News

Silk Road Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Outlook

SUNNYVALE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months and full year ended December 31, 2022. “Our fourth quarter closes the books on a […]

Cleveland Researchers Reveal How Oxygen is Delivered to Tissues, Open Door to New Class of Drugs

Newfound clarity on the longstanding “medical mystery” may lead to new line of drugs for oxygen delivery disorders, including peripheral artery disease, sickle cell disease, heart failure, and others CLEVELAND—Cardiovascular medicine, hematology and pulmonary medicine may soon have the first-ever therapies to correct poor tissue oxygenation, a key driver of […]

Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging

Swoop® Portable MR Imaging® system positioned to offer even greater clinical utility in neurocritical care GUILFORD, Conn., Feb. 28, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable MRI system, today announced the U.S. Food and […]

LATE-BREAKING DATA REINFORCE BENEFITS OF ABBOTT’S MINIMALLY INVASIVE HEART DEVICES

New results presented at Cardiovascular Research Technologies (CRT) 2023 demonstrate the safety of Navitor™ TAVI system and its effectiveness in minimizing blood leakage around the valve implant Latest data continue to show the benefits of Amplatzer™ Amulet™ LAA Occluder’s immediate and complete closure of the LAA compared to Watchman‡ Findings […]

Pulnovo Medical Reports Positive One-year Results for PADN-CFDA Trial in Pulmonary Arterial Hypertension (PAH) Treatment

SHANGHAI, Feb. 27, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced positive one-year results from the Pulmonary Artery Denervation (PADN)-CFDA pivotal study at the industry’s most leading American Cardiovascular Research Technologies conference (CRT 2023). PADN is an innovative radiofrequency ablation technique in treating PH, was recognized as a CFDA […]

New Heart Health Education Components Arrive on OMRON Connect Mobile App

OMRON Healthcare celebrates Heart Health Month with new education components providing tips for AFib identification, quality sleep, healthy recipes, and lifestyle changes that may help reduce heart attack and stroke risk HOFFMAN ESTATES, Ill., Feb. 28, 2023 /PRNewswire/ — Global heart health leader OMRON Healthcare is celebrating Heart Health Month with new […]

ViewRay Announces Fourth Quarter and Full Year 2022 Results

DENVER, Feb. 27, 2023 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) (the “Company”) today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approximately $70.1 million, primarily from ten revenue […]

NovaSignal Donates NovaGuide™ 2 Intelligent Ultrasound to The Jacobs Institute to Advance Stroke Research

Autonomous, robotic transcranial Doppler (TCD) ultrasound is a real-time neuromonitoring tool that can detect and help prevent intraprocedural complications LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) — NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, today announced the donation of a NovaGuide™ […]

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

Single Intra-Myocardial Intervention with Rexlemestrocel-L Reduced Cardiovascular Death, Myocardial Infarction or Stroke Over Mean Follow-Up of 30 Months in High-Risk Patients with Chronic Heart Failure NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the […]